Informed consent in AI-enabled care means patients understand when AI is involved, what it is used for, and what risks or limits may exist. In practice, this requires plain-language explanation, opportunities for questions, and a real ability to opt out when appropriate, so patient choice remains meaningful.
Expanded Definition
Informed consent is not just a signature or a one-time disclosure. In AI-enabled care, it means the person understands that AI is part of the care process, what role it plays, what limits it has, and what choices remain available to them. The boundary matters: a patient can agree to a procedure without understanding that an AI system may influence triage, documentation, risk scoring, or decision support.
There is an important consensus point and an important unresolved one. The consensus is that consent must be understandable, voluntary, and meaningful. The unresolved point is how much AI-specific detail is necessary for consent to be genuinely informed in different clinical contexts. NHIMG treats the minimum standard as plain-language disclosure that is specific enough to shape a real choice, not a generic notice. For legal context, the EU General Data Protection Regulation (GDPR) is relevant where AI processing intersects with personal data rights, although informed consent in care is broader than privacy notice alone.
A common misunderstanding is to treat consent as complete once patients are told “AI may be used.” That wording is too vague to support meaningful understanding, especially when the system affects diagnosis, prioritisation, or follow-up.
Examples and Use Cases
In practice, informed consent shows up at the point where AI changes the care experience in a way a patient would reasonably want to know about.
- A patient is told that an AI tool may assist with radiology review, while the final clinical decision remains with the physician.
- A hospital discloses that AI may help prioritise referrals or triage queues, so the patient understands why timing or routing may differ.
- A telehealth service explains when chat-based AI is drafting notes or summarising symptoms before a clinician reviews them.
- A care pathway includes an opt-out option where AI-supported decision aids are used for convenience, but not as a condition of treatment unless clinically necessary.
- A payer or provider uses AI for administrative matching or eligibility support, and the disclosure clarifies whether the output affects access to care or only internal processing.
The tradeoff is that fuller disclosure can improve trust, but overly technical explanations can defeat comprehension. The practical goal is not volume of information, but enough clarity for a person to decide whether the AI involvement matters to them.
Security Implications
When informed consent is weak, the failure is not only legal or ethical. It can create trust failure, complaint escalation, and hidden resistance from patients who later discover that AI influenced their care. It also creates governance ambiguity, because teams may assume disclosure happened somewhere in the workflow even when the patient never received a clear explanation.
Another consequence is accountability drift. If consent language is vague, it becomes harder to determine whether the patient agreed to AI-assisted processing, whether the disclosure covered the actual use case, and whether opt-out handling was honored. That matters most when AI is used in ways that alter prioritisation, summarisation, or clinical support, because the impact can extend beyond convenience into care timing and patient confidence.
Practitioners should watch for consent text that is copied from a generic privacy notice, because that often signals that the process is documenting permission rather than enabling choice.
Domain and Governance Relevance
In AI-enabled healthcare, informed consent sits at the intersection of patient autonomy, clinical governance, and data processing transparency. It is relevant whenever AI changes how care is presented, prioritised, or supported, because the patient’s decision is only meaningful if the AI role is visible in a way they can understand.
For identity and access workflows, the concept becomes more operational when AI is part of a care platform that uses role-based views, delegated review, or automated summaries. In those settings, governance must ensure the disclosure matches the real system behaviour, not the marketing description of the tool. If a patient believes a human reviewed the case when AI materially shaped the output, the consent model has failed even if the workflow was technically compliant.
NHIMG treats informed consent as a control on trust and expectation management, not just a formality. That is why the disclosure standard should track actual AI involvement, patient comprehension, and whether opting out remains feasible where the clinical context allows it.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST AI 600-1, NIST AI RMF and NIST CSF 2.0 set the technical controls, while EU AI Act and ISO/IEC 42001:2023 define the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| EU AI Act | A1 — Transparency and Information to Users | AI-assisted care disclosure depends on clear user-facing transparency. |
| Recommendation — Disclose AI involvement clearly and keep patient-facing explanations aligned to the system's actual role. | ||
| NIST AI 600-1 | GOV — AI Governance | Consent quality depends on accountable governance for AI use in care delivery. |
| Recommendation — Assign governance for AI disclosures so consent language matches approved clinical use cases. | ||
| NIST AI RMF | MAP — Map the AI Context | You need to identify where AI affects the care pathway before disclosure can be meaningful. |
| Recommendation — Map where AI influences the care workflow and disclose those touchpoints before patient reliance. | ||
| ISO/IEC 42001:2023 | 5.2 — AI policy | Informed consent requires policy-backed control over organisational AI use and disclosure expectations. |
| Recommendation — Set AI policy requirements that define when patient disclosure and opt-out must be provided. | ||
| NIST CSF 2.0 | GV.OV-01 — Oversight of Risk Management Strategy | Consent gaps are a governance issue that affects oversight of AI-related risk and trust. |
| Recommendation — Review AI disclosure practices as part of organisational risk oversight and patient trust governance. | ||
Related resources from NHI Mgmt Group
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on September 7, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
